Business
Stratasys and CollPlant Unite Technologies to Transform Healthcare with Industrial-Scale Bioprinting of Tissues and Organs
Joint development and commercialization agreement will initially focus on development of bioprinting solution for CollPlant’s regenerative breast implants,
About this update from Collplant Biotechnologies Ltd.
[{"type":"text","content":"\nJoint development and commercialization agreement will initially focus on development of bioprinting solution for CollPlant’s regenerative breast implants, addressing $2.6 billion market opportunity\n\n\nStratasys’ P3 technology-based bioprinter and CollPlant’s rhCollagen-based bioinks also ideal for future innovation and production of additional human tissues and organs\n\n\nCompanies to cross-promote respective bioprinting products\n\n\n EDEN PRAIRIE, Minn. & REHOVOT, Israel--(BUSINESS WIRE)--\nStratasys Ltd. (Nasdaq: SSYS) and CollPlant Biotechnologies (Nasdaq: CLGN) today announced a joint development and commercialization agreement to collaborate on the development of a solution to bio-fabricate human tissues and organs using Stratasys’ P3 technology-based bioprinter and CollPlant’s rh-Collagen-based bioinks. The first project focuses on the development of an industrial-scale solution for CollPlant's regenerative breast implants program.\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230404005729/en/Human size breast implant, printed with Stratasys P3 3D printing technology and CollPlant's bioink. (Photo: Business Wire)\nStratasys is a leader in polymer 3D printing solutions. CollPlant is a pioneering regenerative and aesthetics medicine company developing innovative technologies and products based on its plant-based collagen for tissue regeneration and organ manufacturing.\n\n\nThe new bioprinter, based on Stratasys’ precise P3™ 3D printing technology in combination with CollPlant's flagship bioinks, will enable the production of CollPlant’s state of the art breast implants, which are being designed to regenerate an individual’s natural breast tissue without eliciting immune response, providing a potentially revolutionary alternative for both aesthetic and reconstructive procedures.\n\n\nCurrently the global breast implant market is estimated to be $2.6 billion,1 while breast reconstruction and augmentation procedures represent the second most common plastic surgery procedure performed worldwide today2. The most common breast augmentation or reconstruction procedures today are based on synthetic silicone breast implantations, an artificial substitution for natural regenerated tissue with risks of complications.\n\n\nUnder the agreement, both companies have ...